Subscribe

What can be done to alleviate the cost to patients with cancer

VBCC - Media Library - Pricing
Michael Kolodziej, MD
National Medical Director
Oncology Solutions
Aetna
Hartford, CT

The fashion by which we do help patients recognize the path to making a good, value‑driven decision requires several things that are not in the system right now. The first is price transparency. It is totally unbelievable how little providers and patients know about how much things cost.

That’s got to change. There’s the stuff in the public press all the time about people shopping around for how much it will cost to have your gallbladder removed, or something like that, and people cannot get that information, and if they got that information, they’d be horrified because it’s so variable.

In addition to considerations of transparency and cost, there needs to be some improvement in the ability to communicate with patients, educating patients about the real outcome associated with a certain decision.

This especially is relevant in cancer, when the patient has an incurable, advanced malignancy, and choices may have wildly different value propositions associated with them, both in terms of cost and what it costs the patient, in terms of quality of life, the impact on family, and financial toxicity.

We’ve got to improve transparency, and we’ve got to improve the way we talk to patients, and help them get involved in the shared decision-making.

Related Items
The Role of Oncologists in Defining the Value of Cancer Therapy
Michael Kolodziej, MD
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Affordability + Clinical Effectiveness = The Value Equation
C. Daniel Mullins, PhD
VBCC - Media Library published on March 25, 2015 in Pricing
Providing Patients with Cost Information
C. Daniel Mullins, PhD
VBCC - Media Library published on March 25, 2015 in Pricing
New Conversations About Costs of Cancer Care
C. Daniel Mullins, PhD
VBCC - Media Library published on March 25, 2015 in Pricing
Keeping Cost Out of the Drug Approval Debate
Andrew Stainthorpe, PhD
VBCC - Media Library published on March 25, 2015 in Pricing
Value-Based Concerns of European Oncologists
Andrew Stainthorpe, PhD
VBCC - Media Library published on March 25, 2015 in Pricing
Approaches to Alleviating Costs for Patients and Payers
Andrew Stainthorpe, PhD
VBCC - Media Library published on March 25, 2015 in Pricing
Value-Based Concerns - What Matters?
Linda Bosserman, MD, FACP
VBCC - Media Library published on March 25, 2015 in Pricing
Cost Is Crucial When Evaluating Treatment
Linda Bosserman, MD, FACP
VBCC - Media Library published on March 25, 2015 in Pricing
The Imperative to Discuss Cost of Care with Patients with Cancer
Michael Kolodziej, MD
VBCC - February 2015, Vol 6, No 1 published on February 19, 2015 in VBCC Perspectives
Last modified: September 29, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology